Brief: MedinCell: Clinical Phase 3 Trial For mdc‑TJK To Be Initiated

Medincell SA

29/08/2022 17:17

Aug 29 (Reuters) - Medincell SA  MEDCL.PA :
    * PHASE 3 STUDY TO BE INITIATED FOR SECOND LONG-ACTING
INJECTABLE
ANTIPSYCHOTIC USING MEDINCELL’S TECHNOLOGY
    * MEDINCELL WILL RECEIVE IMMEDIATELY A $3 MILLION PAYMENT
FROM
TEVA PHARMACEUTICALS LINKED TO PROJECT DEVELOPMENT MILESTONE.
    * MDC-TJK FOLLOWS MDC-IRM (LAI RISPERIDONE), FIRST
SUBCUTANEOUS
ANTIPSYCHOTIC BASED ON MEDINCELL'S TECHNOLOGY CURRENTLY UNDER
REGULATORY REVIEW BY U.S. FDA, WITH A LAUNCH TARGET SET FOR 2023
    * PHASE 3 STUDY WILL ASSESS THE EFFICACY AND SAFETY OF
POTENTIALLY
FIRST SUBCUTANEOUS LONG-ACTING INJECTABLE (LAI) FORMULATION OF
OLANZAPINE FOR TREATMENT OF PATIENTS WITH SCHIZOPHRENIA

Source text for Eikon:  ID:nBw9m3NKZa 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))